Corixa, Beaufour Ipsen Group deal

CRXA granted Beaufour exclusive worldwide rights to its AnergiX.MG T cell inactivation technology to treat myasthenia gravis, an autoimmune neuromuscular disease. Beaufour is responsible for clinical ...